Identifying whether specific subtypes undergo neurodegeneration following Chd7 deletion and gaining insights into the disruption of tonotopy may guide improvements in cochlear implants for CHARGE syndrome patients. This evidence concerns the gene CHD7 and CHARGE syndrome.